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Figure 1) Representative micrographs of the medial tibial plateau (bot-
tom) and medial femoral condyle (top) from study # 3. 50X original
magniﬁcation
Figure 2) Quantitation of the effects of rhGDF5 intra-articular therapy on
signiﬁcant cartilage lesion width of the medial tibial plateau. Day 21
untreated group indicates the extent of cartilage erosion present at the
onset of therapy. Data represent 15 rats/group from study # 3.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S471were revealed to be more predictive of a patient receiving TKA than the
other scores. Osteophyte, at least in patients with end-stage knee OA,
may induce disability of daily living, associating the determination of
the patients for receiving TKA. In conclusion, when we evaluate the
structural changes due to knee OA by MRI, osteophytes score is only a
predictor for receiving TKA.
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THE RESULTS OF MODIFIED DISTRACTION ARTHROPLASTY FOR
DEGENERATED OSTEOARTHRITIS OF THE ANKLE
N. Usami V y,z, H. Ikezawa z. yUsami Orthopedic Clinic for Foot, AnZkle and
Shoe Disorders, Tokyo, Japan; zDept. of Orthpedic Surgery, Keio Univ.,
Tokyo, Japan
Purpose: In the treatment of degenerated osteoarthritis of the ankle,
we obtained good results in terms of preserving the joint functions and
relieving pain by performing a procedure to reconstruct the anatomical
structure of the ankle, accompanied by ROM exercises undertaken with
the joint space kept pulled apart with a conventionally used external
ﬁxator.
Methods: A total of 43 patients (45 ankles; 28 ankles in 28 male
patients and 17 ankles in 15 female patients) who underwent the
procedure from 1998 to 2012 were enrolled in the study. The patients
were 18-72 years old, with a mean age of 56 years at the time of the
procedure. In regard toTakakura’s classiﬁcation, 6 ankles were classiﬁed
as Stage 2, 21 as Stage 3a, 12 as Stage 3b, and 6 as Stage 4. The patients
underwent debridement by the conventional method, including
removal of bone spurs and synovectomy, combined with low tibial
osteotomy, osteochondral graft, drilling and/or reconstruction of ankle
lateral ligaments. As post-treatment, patients were started on active
ROM exercises from the day after the surgery and started partial weight
bearing at 6-8 weeks after the surgery. The external ﬁxation device was
removed to allow total weight bearing at 3 months. Follow-ups were
performed for 1-8 years, with a mean of 4 years and 7 months.
Results: The pain severity did not change in 2 ankles. For the remaining
43 ankles in which the pain improved, no problems in daily life activ-
ities, but inability to undertake sports activities were observed for 31
ankles, while no problems in either physical work or sporting activities
for 12 ankles. None of the patients took painkiller. Improvements of the
ROMwere seen in 10 ankles, while no change of the ROMwas observed
in the remaining 35 ankles. There were no patients who needed addi-
tional operations such as arthrodesis during the follow-up period.
Conclusions: Procedures such as arthrodesis, total ankle replacement
and low tibial osteotomy are performed to treat degenerated osteo-
arthritis of the ankle, but each of these is associated with problems,
including those related to the qualifying age, durability, and range of
motion. It is difﬁcult to select a proper treatment option, especially for
relatively young patients. In contrast, there is no age requirement for
the procedure described in this study, because joint functions are pre-
served by restoring the patients’ own tissue and the patients suffered
only mild postoperative limitation of the ADL. As demerits, this pro-
cedure is less effective for pain relief than arthrodesis and more
abundant experience is required, because several kinds of surgical
procedures have to be performed. However, it can be indicated for
young patients in whom preservation of the joint functions and higher
activity potential are required. In addition it is well applicable to
degenerated osteoarthritis of the ankle that arises at a relatively early
age, because future joint replacement or arthrodesis will not be difﬁcult
in patients who undergo this procedure.
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INTRA-ARTICULAR SUPPLEMENTATION WITH RECOMBINANT
HUMAN GDF5 ARRESTS DISEASE PROGRESSION AND STIMULATES
CARTILAGE REGENERATION IN THE RAT MEDIAL MENISCUS
TRANSECTION (MMT) MODEL OF OSTEOARTHRITIS
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A.M. Bendele x, B.J. Story y. yDePuy Synthes Mitek Sports Med., Raynham,
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Purpose: Genome-wide association studies and investigation of
osteoarthritis (OA) risk alleles suggest that reduced levels of functional
Growth and Differentiation Factor 5 (GDF5) expression in tissues of the
joint may be a precipitating factor contributing to OA. Therefore, wehypothesized that supplementation of rhGDF5 to the OA joint via intra-
articular injection may represent a viable therapeutic approach.
Methods: We used a rat medial meniscus transection (MMT) model of
OAwhich causes rapid and progressive OA-like pathology including the
aggressive erosion of articular cartilage. Three studies were conducted
(n ¼ 15 / treatment group) to investigate the feasibility of rhGDF5 in
either a preventative or therapeutic modality: (1) 6 weekly injections
beginning on day 3 post MMT with termination on day 42 (pre-
ventative), (2) 6 weekly or 3 bi-weekly injections beginning on day 21
post MMT with termination on day 63 (therapeutic), and 3) a single
injection, or a series of 2 or 3 bi-weekly injections, beginning on day 21,
with termination on day 63 (therapeutic). rhGDF5 doses ranging from
0.3 to 100 mg were studied, using a glycine buffered trehalose vehicle
(pH¼3.0). Joints were harvested and processed for histological analysis
following toluidine blue staining. Quantitative and semi-quantitative
histopathological end points were used to evaluate the extent of OA
progression in the medial tibial plateau cartilage.
Results: rhGDF5 demonstrated signiﬁcant dose-dependent cartilage
protection as a preventative therapy (Study 1). In particular, the width
of signiﬁcant tibial lesions was reduced by 11% by repeat treatment with
0.3 mg rhGDF5, 22% by 3 mg, 32% by 10 mg, and 49% by 30 mg injections
when compared with vehicle controls. Study 2 demonstrated dose-
dependent efﬁcacy of rhGDF5 compared with vehicle controls when
administered in a therapeutic modality beginning on day 21 post MMT.
Following 6 weekly injections, the width of signiﬁcant tibial lesions was
reduced by 30% by a 10 mg rhGDF5 dose and by 47% by a 30 mg dose.
